Posts Tagged ‘brainstorm’

ALS adult stem cell trial = safe and effective | Reuters

In VICTORIES & SUCCESS STORIES on January 19, 2012 at 9:28 am

(Reuters) – Data from the first ALS patients in a clinical trial treated with BrainStorm Cell Therapeutics adult stem cell therapy did not show significant side effects and the treatment has so far proven to be safe, the company said on Tuesday.

Israel-based BrainStorm is developing NurOwn for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s Disease, a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord.

The U.S. Food and Drug Administration last year granted orphan drug designation to NurOwn. The FDA’s orphan drug program encourages the development of treatments for rare diseases by providing financial incentives.

“There have been no significant side effects in the initial patients we have treated with BrainStorm’s NurOwn technology,” said Dimitrios Karussis, the head of Israel’s Hadassah Medical Center’s Multiple Sclerosis unit, who is leading the clinical trial.

“In addition, even though we are conducting a safety trial, the early clinical follow-up of the patients treated with the stem cells shows indications of beneficial clinical effects, such as an improvement in breathing and swallowing ability as well as in muscular power.”

Patients in the trial are transplanted with stem cells derived from their own bone marrow and treated with the NurOwn stem cell technology.

The initial phase of the study is designed to establish the safety of NurOwn and will later be expanded to assess efficacy.

“Based on the interim safety report, the hospital ethical and safety committee granted the company approval to proceed with treating the next patients,” said Chaim Lebovits, president of BrainStorm.

According to the ALS Association, 5,600 people in the United States are diagnosed with the disease each year. It is estimated that as many as 30,000 Americans may have the disease — which has severely disabled British physicist Stephen Hawking — at any given time.

BrainStorm sees positive data in ALS stem cell trial | Reuters.

Muhammad Ali seeks ADULT STEM CELL treatment in Israel

In VICTORIES & SUCCESS STORIES on February 26, 2010 at 7:47 pm

After years of waiting for an embryonic stem cell treatment, Muhamad Ali has finally accepted that ADULT STEM CELL treatments are the only way he is going to get better.  Thank god!  Michael J Fox, please pay attention! -dg


Muhammad Ali seeks ADULT STEM CELL treatment

by Graciemag Newsroom — February 23, 2010.

More American boxing legend Muhammad Ali will undergo a new type of treatment for Parkinson’s syndrome, a disease that has debilitated his health for decades.

The former pugilist’s daughter, Rashida Ali, revealed that her father is keen to try the treatment using [adult] stem cells. “Muhammad Ali’s daughter contacted us after hearing of our work with adult stem cells and assured us her father wants to take part in the tests we are doing.”

The treatment, initially meant for patients suffering from sclerosis, may be amplified to treat Pakinson’s disease patients, like the pugilist.

The tests performed on rats to combat sclerosis, including Parkinson’s, were a success. The next step is to prove its effectiveness on humans.


Muhammad Ali ended his career as a champion heavyweight in 1981. In 1984 he was diagnosed with the disease, which seriously affects one’s ability to communicate. Rumors abound that the head trauma from boxing caused the Parkinson’s, but was never scientifically proven.

Also see:

Oz, Oprah, Michael J Fox and Embryonic Stem Cell Research


Check out the video on Youtube of highlights from the legendary athlete’s career.  Click on the title of this article to open in a new page and see the video in larger format:

via Graciemag International » Muhammad Ali seeks treatment in Israel.


In BUSINESS OF STEM CELLS on November 15, 2009 at 11:30 pm


BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that its chief medical advisor, Professor Eldad Melamed, was interviewed on November 9, 2009 on Israel?s most popular radio broadcast, Galei Zahal. The interview was conducted by Yaron Willensky, a respected news talk show host, to discuss the latest achievements, treatment and progress of BrainStorm?s stem cell technology and therapy with respect to neurodegenerative diseases such as ALS and Parkinson?s disease.

?The stem cell therapy treatment is ready. We have successfully been able to process autologous adult human mesenchymal stem cells, grow them and differentiate them into other cell types for the treatment of neurodegenerative diseases. We are currently in middle of obtaining approval to begin the first clinical trials on ALS patients in Israel,? stated Professor Melamed during the interview. ?Regarding clinical trials for Parkinson?s disease, we are ready to begin,? continued Professor Melamed. ?However, we must still complete the regulatory approval process before that can happen.?


BrainStorm Reschedule Webcast Audio Conference

In BUSINESS OF STEM CELLS on October 15, 2009 at 12:27 pm

NEW YORK & PETACH TIKVAH, Israel–(Business Wire)– BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI – News) , announced today that it will reschedule the webcast audio conference to update shareholders on its strategy and report on the way forward towards clinical trials. This event will be rescheduled for a later date to be announced soon. We apologize for any inconvenience.

via BrainStorm Announces That It Will Reschedule Its Webcast Audio Conference | Reuters.


Stem cell production deal boosts Brainstorm’s share

In BUSINESS OF STEM CELLS on September 6, 2009 at 11:47 am

The move brings Brainstorm a step closer to a clinical trial for its ALS product.

Gali Weinreb6 Sep 09 12:52

Despite falling 30% on Thursday and Friday, Brainstorm Cell Therapeutics Ltd. (Bulletin Board:BCLI.OB), a developer of adult stem cell technologies and therapeutics for neurodegenerative diseases, still saw its share rise 60% over last week after reporting a production deal. The share closed at $0.24 on Friday, giving a market cap of $14.35 million.

Brainstorm said that it had agreed to start production with Protein Production Services Ltd. (PPS), a manufacturing contractor. The clinical-grade product will be used in a pre-clinical safety trial for the company’s innovative therapy for ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease).

via Stem cell production deal boosts Brainstorm’s share.

BCLI,CVIT,CVITE,NWMT,NPHC – NewMarket Technology – September 2, 2009

In BUSINESS OF STEM CELLS on September 3, 2009 at 10:24 am

Weston, FLA, Sep 02, 2009 (M2 PRESSWIRE via COMTEX) — NPHC | Quote | Chart | News | PowerRating — Wall Street News Alert's “stocks to watch” this morning are: NewMarket Technology, Inc. (OTC: NWMT), Cavit Sciences Inc. (OTC: CVIT), BrainStorm Cell Therapeutics Inc (OTCBB: BCLI | Quote | Chart | News | PowerRating) and Nutra Pharma Corp. (OTCBB: NPHC).

via BCLI,CVIT,CVITE,NWMT,NPHC Wall Street News Alert: Stock Watch for Wednesday: NewMarket Technology – September 2, 2009.

BrainStorm Taps Israeli firm for Stem Cell Production

In BUSINESS OF STEM CELLS on August 31, 2009 at 11:29 am

BrainStorm Cell Therapeutics Taps Israeli CMO for Stem Cell Production

GEN News Highlights

BrainStorm Cell Therapeutics inked a deal with Israeli firm Protein Production Services for cGMP production of its stem cell therapeutic for amyotrophic lateral sclerosis (ALS). The clinical-grade product will be used in a preclinical safety trial.

“As we announced on August 24 after securing new funding, BrainStorm now has both the financing and the production capabilities to achieve our goal of reaching human clinical studies in the coming year,” notes Rami Efrati, CEO.

BrainStorm’s technology allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. It has reportedly been tested on various animal models of neurodegenerative diseases.

The firm’s current focus is on ALS and Parkinson’s. The technology can be leveraged for treating other diseases including MS, Huntington’s disease, and stroke, according to BrainStorm Cell Therapeutics.

The company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University, the technology transfer arm of the university.

via News: BrainStorm Cell Therapeutics Taps Israeli CMO for Stem Cell Production ..

%d bloggers like this: